Angina Pectoris Drugs Market Size – By Type, By Drug Class, By Route of Administration, By Distribution Channel, Global Forecast, 2025 – 2034

Angina Pectoris Drugs Market Size

The global angina pectoris drugs market size was valued at USD 12.3 billion in 2024 and is estimated to grow at a CAGR of 4.1% from 2025 to 2034. The growth of this market is driven by a variety of factors including an increasing prevalence of cardiovascular diseases, advancements in drug therapies, and a growing aging population.
 

One of the primary drivers of market growth is the increasing lifestyle-related risks, such as obesity, sedentary behavior, unhealthy diets, smoking, and stress. These factors contribute to the rise in cardiovascular diseases, including angina, by increasing the prevalence of conditions like high blood pressure and diabetes. As modern lifestyles continue to lead to poor heart health, more individuals are at risk of angina, driving the demand for treatments.
 

In addition, improved diagnosis and awareness of angina and cardiovascular health are also boosting market growth. Moreover, the expansion of healthcare access, particularly in emerging markets, is enabling more people to seek treatment for angina. Thus, as healthcare infrastructure improves globally, the accessibility of angina drugs is growing, further stimulating the market.
 

Angina pectoris drugs are medications used to manage chest pain and improve heart function by enhancing blood flow or reducing the heart's oxygen demand. Common drug classes include nitrates, beta-blockers, calcium channel blockers, anticoagulants, and antiplatelet agents. These drugs alleviate symptoms, prevent episodes, and reduce the risk of severe cardiovascular events.
 

Angina Pectoris Drugs Market Trends

Rising prevalence of cardiovascular diseases is a key trend driving the growth of the market.
 

• According to the British Heart Foundation, approximately 620 million people worldwide are living with heart and circulatory conditions, with around 60 million new cases developing each year. Globally, 1 in 13 individuals is estimated to have a heart or circulatory disease. These conditions are a leading cause of mortality, accounting for 1 in 3 deaths globally—around 20.5 million deaths in 2021, equivalent to 56,000 deaths per day or one death every 1.5 seconds.
   
• This high prevalence of cardiovascular diseases significantly drives the demand for effective treatment options including angina pectoris drugs.
   
• Additionally, factors such as sedentary lifestyles, unhealthy diets, obesity, smoking, diabetes, and aging populations contribute significantly to this rising burden, thereby driving the market growth.
   
• Furthermore, growing research and development initiatives are leading to advancement in drug development, thereby contributing to the market growth.
   

Angina Pectoris Drugs Market Analysis

Based on type, the global market is segmented into stable angina, unstable angina, microvascular angina, and prinzmetal angina. The stable angina segment accounted for significant market share of 51.3% in 2024.
 

• Stable angina is the most common form of angina, characterized by predictable chest pain triggered by physical activity or emotional stress. Its high prevalence among patients with coronary artery disease significantly contributes to its market dominance.
   
• Secondly, the availability of well-established treatment protocols, including nitrates, beta blockers, and calcium channel blockers, supports effective management, boosting drug adoption rates.
   
• Additionally, growing awareness and improved diagnostic capabilities have increased the number of diagnosed cases, further driving segment growth.
   

Based on drug class, the angina pectoris drugs market is categorized into beta blockers, nitrates, anti-platelets, calcium channel blockers, anticoagulants, ACE inhibitors, and other drug classes. The beta blockers segment was valued at USD 3.7 billion in 2024.
 

• Beta blockers are widely recognized as first-line therapy for angina pectoris, particularly for stable angina, as they effectively reduce heart rate, lower myocardial oxygen demand, and improve exercise tolerance.
   
• Additionally, their broad clinical application and proven efficacy make them a cornerstone of angina treatment.
   
• The segment's growth is further supported by the high prevalence of cardiovascular risk factors such as hypertension and coronary artery disease, where beta blockers are frequently prescribed.

Based on route of administration, the angina pectoris drugs market is divided into oral, injectable, and topical. The oral segment dominated the market and is expected to grow at 4% CAGR over the analysis period.
 

• Most first-line treatments for angina, such as beta blockers, nitrates, and calcium channel blockers, are available in oral formulations, ensuring wide accessibility.
   
• Oral medications generally have lower production and distribution costs, making them more affordable for both healthcare systems and patients.
   
• Additionally, angina pectoris often requires long-term treatment, making oral drugs ideal for daily use without the need for clinical visits.
   
• Owing to the above-mentioned factors the oral segment is anticipated to witness growth in coming years.
   

Based on distribution channel, the angina pectoris drugs market is classified into hospital pharmacies, retail pharmacies and online pharmacies. The hospital pharmacies segment accounted for 49.2% of market share in 2024.
 

• Hospitals provide direct access to specialized care, including advanced drug formulations, injectable therapies, and comprehensive treatment plans tailored to patients with unstable angina or comorbidities. The ability to offer urgent care and high-strength medications ensures hospital pharmacies are crucial in treating severe angina cases, thereby driving their market share.
   
• Moreover, the growing prevalence of cardiovascular diseases has led to an increase in hospital admissions for angina-related complications, further boosting the demand for medications dispensed through hospital pharmacies.

The U.S. angina pectoris drugs market was valued at USD 4.6 billion in 2024.
 

• According to the National Institutes of Health, about 10 million people in the U.S. have angina, a major symptom of coronary artery disease, and approximately 500,000 new cases are diagnosed each year. This high and increasing prevalence drives the demand for effective medications to manage angina, contributing to the market's substantial value.
   
• Additionally, the U.S. leads in medical research, with continuous innovations in angina therapies, such as beta blockers, nitrates, and advanced combination treatments. These advancements offer more effective treatment options, which drive market growth.
   

Germany angina pectoris drugs market is predicted to witness remarkable growth over coming years.
 

• Germany has one of the most rapidly aging populations in Europe, with a significant portion of the population over the age of 65. As cardiovascular diseases, including angina, are more common among older individuals, the aging demographic will continue to increase the demand for angina medications.
   
• Further, the country is known for its highly advanced healthcare infrastructure, with access to high-quality medical treatments and medications. The availability of cutting-edge treatments and widespread adoption of new therapies in the healthcare system are factors that contribute to the growth of the market.
   

India is projected to grow significantly during the forecast period.
 

• The growth of this market is attributed to the increasing prevalence of cardiovascular diseases, driven by rising obesity rates, diabetes, hypertension, and lifestyle factors such as unhealthy diets and sedentary habits.
   
• Additionally, improved healthcare infrastructure, greater healthcare awareness, and government initiatives like Ayushman Bharat are making angina treatments more accessible across the country, particularly in rural areas.
   

Brazil's angina pectoris drugs market is expected to experience growth over the analysis period.
 

• Brazil's aging population is contributing to a higher number of people suffering from age-related cardiovascular conditions like angina. As the proportion of elderly individuals rises, more people will require medications to manage their heart health.
   
• Additionally, the country is working towards expanding its healthcare system through programs like SUS (Sistema Único de Saúde), which provides affordable healthcare to a significant portion of the population. This will increase accessibility to angina treatments, leading to market growth.
   

Saudi Arabia angina pectoris drugs market is poised to grow in coming years.
 

• As Saudi Arabia continues to urbanize, lifestyle changes like reduced physical activity and unhealthy eating habits are contributing to the growth of cardiovascular diseases. This urbanization trend is expected to boost the demand for angina treatments.
   
• Additionally, factors such as increased awareness and focus on preventive care, government healthcare initiatives, and growing prevalence of cardiovascular diseases further supports the growth of this market.
   

Angina Pectoris Drugs Market Share

The market is highly competitive, with several global pharmaceutical companies leading the market. These companies are continuously investing in research and development to introduce new and improved treatments for angina, addressing the evolving needs of patients. With the increasing focus on cardiovascular health, partnerships and collaborations between pharmaceutical companies, healthcare providers, and research institutions are likely to drive innovation and contribute to the market's growth in the coming years.
 

Angina Pectoris Drugs Market Companies

Few of the prominent players operating in the angina pectoris drugs industry include:

• AdvaCare Pharma
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Eli Lilly and Company
• Gilead Sciences
• GlaxoSmithKline
• Merck
• Novartis
• Otsuka Pharmaceutical
• Pfizer
• Sanofi
   

Angina Pectoris Drugs Industry News

• In March 2022, Zydus Lifesciences received final approval from the U.S. FDA to market nitroglycerin sublingual tablets in 0.3 mg, 0.4 mg, and 0.6 mg. These tablets are indicated for the relief of chest pain (angina) in patients with coronary artery disease. This approval helped the company to broaden its product portfolio and boost revenue growth.
   

The angina pectoris drugs market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Stable angina
• Unstable angina
• Microvascular angina
• Prinzmetal angina

Market, By Drug Class

• Beta blockers
• Nitrates
• Anti-platelets
• Calcium channel blockers
• Anticoagulants
• ACE inhibitors
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable
• Topical

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE